The Human Medicines Committee (CHMP) of the European Medicines Agency (EMA) approved an additional manufacturing site for its production Johnson & Johnson vaccinefor coronavirus, developed by Janssen-Cilag International NV.
Located in West Point, Pennsylvania in the United States, it is operated by Merck Sharp & Dohme Corp and will produce final product. This site is expected to support the continued supply of Janssen COVID-19 vaccine to European Union, broadcasts by ΑΠΕ ΜΠΕ.
This approval does not require a decision of the European Commission and the site may be used right now.
Please note that the EMA is located at continuous dialogue with all COVID-19 vaccine marketing authorization holders as they seek to increase their capacity to supply vaccines. The Agency shall provide guidance and advice on the evidence required to support and expedite applications for the addition of new plants or to increase the capacity of existing plants to produce high quality COVID-19 vaccines.
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
